Cellectis (CLLS) Net Income towards Common Stockholders Growth (3y) (2018 - 2026)
Powered by 
Analysis
Cellectis (CLLS) Net Income towards Common Stockholders Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 91.31% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 17.25% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.89% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 37.44% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -38.56% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 62.15% |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -10.38% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.38% |
| Mar 31, 2026 | 15.73% |
| Dec 31, 2025 | 97.87% |
| Sep 30, 2025 | 26.43% |
| Jun 30, 2025 | -7.80% |
| Mar 31, 2025 | 17.38% |
| Dec 31, 2024 | 30.78% |
| Sep 30, 2024 | 14.90% |
| Jun 30, 2024 | 14.14% |
| Mar 31, 2024 | 35.28% |
| Dec 31, 2023 | -46.05% |
| Sep 30, 2023 | 16.75% |
| Jun 30, 2023 | 28.67% |
| Mar 31, 2023 | -51.80% |
| Dec 31, 2022 | 10.35% |
| Sep 30, 2022 | -21.18% |
| Jun 30, 2022 | 17.26% |
| Mar 31, 2022 | -27.91% |
| Dec 31, 2021 | -2.70% |
| Sep 30, 2021 | -17.94% |